FDA Updates Highlighting the Latest Cancer Treatments : Oncology Times
An abstract is unavailable.
An abstract is unavailable.
The FDA has granted accelerated approval to lisocabtagene maraleucel for the treatment of select adult patients with relapsed or refractory follicular lymphoma.
Supported by an independent educational grant from AbbVie Inc. Join Drs Camidge and Dagogo-Jack in Chicago as they discuss the latest information on MET-altered NSCLC.…
Registration is now open
Open access journal of the Ferrata-Storti Foundation, a non-profit organization Open access journal of the Ferrata-Storti Foundation, a non-profit organization University of North Carolina School…
Randomized clinical trials (RCTs) define the efficacy of new cancer treatments and drive changes in clinical practice. Although the role of RCTs in generating knowledge…
Register now and explore groundbreaking advancements in breast cancer treatment at PBCC 2024. Stay informed with the latest innovations shaping the future of breast cancer…
Rita Beier, MD, Hannover Medical School, Hannover, Germany, summarizes the results of a retrospective analysis evaluating the impact of treosulfan versus busulfan-based conditioning regimens in…
The OncoAlert Newsletter is now out for June 23-29, 2023
The International Journal of Cancer is a cancer journal from the Union for International Cancer Control covering experimental and clinical cancer research.
The increasing number of approved treatment combinations for metastatic renal cell carcinoma highlights the need for actionable biomarkers to guide treatment selection. In this issue…